Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%
4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】
Earnings ReportDaito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending May 2025 (June 2024 to February 2025) dropped 34.9% from the same period last year to 2.03 billion yen.
In addition, the full-year consolidated ordinary profit has decreased 25.7%, from the previous forecast of 3.5 billion yen to 2.6 billion yen (compared to 3.92 billion yen in the previous period), leading to an increase in the profit decline rate from 10.8% to 33.7%.
Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit for the December to May period (2H) has decreased 44.3%, from the previous forecast of 2.03 billion yen to 1.13 billion yen (compared to 1.6 billion yen in the same period of the previous year). This changes the outlook from an anticipated profit increase to a projection of a 29.8% decrease in profit.
In the most recent three-month period, from December to February (3Q), the consolidated ordinary profit dropped to 0.56 billion yen, a 30.3% decrease compared to the same period last year. The operating profit margin drastically worsened from 7.7% in the same period last year to 3.3%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jun - Feb, 2022 | 34,570 | 4,106 | 4,077 | 2,660 | 84.1 | 78.9 | Apr 13, 2023 | J-GAAP |
Jun - Feb, 2023 | 34,662 | 3,105 | 3,122 | 2,339 | 74.2 | 79.6 | Apr 12, 2024 | J-GAAP |
Jun - Feb, 2024 | 36,609 | 1,869 | 2,033 | 1,217 | 39.9 | 78.2 | Apr 14, 2025 | J-GAAP |
YoY | +5.6% | -39.8% | -34.9% | -48.0% | -46.3% |
Guidance Update
Second Half Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - May, 2024 Prev | 24,416 | 2,029 | 2,030 | 1,392 | 46.4 | 17.50 | Jan 10, 2025 | J-GAAP |
Dec - May, 2024 New | 24,416 | 979 | 1,130 | 592 | 19.8 | 17.50 | Apr 14, 2025 | J-GAAP |
Revision Rate | 0.0% | -51.7% | -44.3% | -57.5% | -57.5% |
Full Year Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
May, 2025 Prev | 49,000 | 3,500 | 3,500 | 2,300 | 76.7 | 35 | Jul 12, 2024 | J-GAAP |
May, 2025 New | 49,000 | 2,450 | 2,600 | 1,500 | 50.0 | 35 | Apr 14, 2025 | J-GAAP |
Revision Rate | 0.0% | -30.0% | -25.7% | -34.8% | -34.8% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - May, 2023 | 22,785 | 1,605 | 1,609 | 1,743 | 55.5 | 15 | Jul 12, 2024 | J-GAAP |
Dec - May, 2024 Guidance | 24,416 | 979 | 1,130 | 592 | 19.8 | 17.50 | Apr 14, 2025 | J-GAAP |
YoY | +7.2% | -39.0% | -29.8% | -66.0% | -64.4% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
May, 2023 | 45,101 | 5,207 | 5,169 | 3,600 | 113.8 | 27.27 | Jul 14, 2023 | J-GAAP |
May, 2024 | 46,895 | 3,894 | 3,923 | 3,295 | 105.0 | 30 | Jul 12, 2024 | J-GAAP |
May, 2025 Guidance | 49,000 | 2,450 | 2,600 | 1,500 | 50.0 | 35 | Apr 14, 2025 | J-GAAP |
YoY | +4.5% | -37.1% | -33.7% | -54.5% | -52.4% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 10,552 | 816 | 808 | 787 | 25.0 | 7.7 | Apr 12, 2024 | J-GAAP |
Mar - May, 2024 | 12,233 | 789 | 801 | 956 | 30.5 | 6.4 | Jul 12, 2024 | J-GAAP |
Jun - Aug, 2024 | 12,678 | 849 | 983 | 618 | 20.2 | 6.7 | Oct 11, 2024 | J-GAAP |
Sep - Nov, 2024 | 11,906 | 622 | 487 | 290 | 9.5 | 5.2 | Jan 10, 2025 | J-GAAP |
Dec - Feb, 2024 | 12,025 | 398 | 563 | 309 | 10.1 | 3.3 | Apr 14, 2025 | J-GAAP |
YoY | +14.0% | -51.2% | -30.3% | -60.7% | -59.5% |
Related Articles
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year
VALUE CREATION, 50% Increase in Ordinary Profit, Record High for The First Time in Two Years, Dividend Raised by 0.5 yen
KAWAKAMI PAINT, Dec-Feb (1Q) Ordinary Profit Turns to Loss
AFC-HD AMS Life Science, First Half Ordinary Profit Increases by 26%, Dec-Feb Ordinary Profit Increases by 10%
Life Foods, 52% Decrease in Ordinary Profit for The Current Fiscal Year, Resuming Dividends at 5 yen for the First Time in five terms., Plan to Continue the 5 yen Policy This Fiscal Year as Well
KAITORI OKOKU, 17% Increase in Ordinary Profit, Record High for The First Time in Two Years
TOKYO KOKI, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 4.7 times Increase in Ordinary Profit for The Current Fiscal Year